Claims

1. Pharmaceutical preparation containing as an active agent a pharmacologically acceptable salt of dichloromethylene bisphosphonic acid, **characterized** in that it is an oral solid dosage form comprising silicified microcrystalline cellulose.

2. Preparation according to claim 1, **characterized** in that it comprises 5-25 % by weight of silicified microcrystalline cellulose.

3. Preparation according to claim 1, **characterized** in that it comprises
a) from about 60 to 80 % by weight of anhydrous disodium clodronate;
b) from about 8 to 20 % by weight of silicified microcrystalline cellulose; and
c) from about 0.5 to 10 % by weight of lubricants and/or disintegrants.

4. Preparation according to ~~any one of the preceding claims~~ claim 1 wherein silicon dioxide is present in the silicified microcrystalline cellulose in an amount of from about 0.1 to 20 % by weight, based on the weight of the microcrystalline cellulose.

5. Preparation according to ~~any one of the preceding claims, characterized~~ claim 1 in that it is a tablet or capsule.

6. Preparation according to ~~any one of the preceding claims~~ claim 1, **characterized** in that the salt of dichloromethylene bisphosphonic acid is the disodium salt.

7. Process for the manufacture of a pharmaceutical preparation according to claim 1 **characterized** in that a wet granulation technique is used.

8. Process for the manufacture of a pharmaceutical preparation according to claim 1, **characterized** in that a dry granulation technique is used.

9. Process for the manufacture of a pharmaceutical preparation according to claim 1, **characterized** in that a direct compression technique is used.

10. Use of silicified microcrystalline cellulose for the manufacture of a pharmaceutical preparation containing as an active agent a pharmacologically acceptable salt of dichloromethylene bisphosphonic acid.

add B1 add C1